Effect of age and gender on the safety, tolerability, and pharmacokinetics of BAY 12-9566 in healthy subjects

Journal of Clinical Pharmacology

Volumn 41, Issue 7, 2001, Pages 764-769

  Lathia, C ^a   Shah, A ^a   Sundaresan, P ^a  

^a BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TANOMASTAT;

ADULT; ADVERSE DRUG REACTION; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FEMALE; GENDER; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; STRUCTURE ANALYSIS;

ADULT; AGE DISTRIBUTION; AGED; AGING; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; DOUBLE-BLIND METHOD; FEMALE; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; ORGANIC CHEMICALS; SEX DISTRIBUTION;

EID: 0034963105     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700122010672     Document Type: Article

References (23)

1. Osteoarthritis
2. Epidemiologic and etiologic approach of osteoarthritis
3. Osteoarthritis: Clinical features and treatment
4. Osteoarthritis: Symptoms and signs
5. Levels of metalloproteases and tissue inhibitor of metalloproteases in human osteoarthritic cartilage
6. Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage
7. Matrix metalloproteinases and their inhibitors in connective tissue remodeling
8. Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis
9. Biochemical considerations
10. Osteoarthritis in the human knee: A dynamic process of cartilage matrix degradation, synthesis and reorganization
11. Inhibition of articular cartilage degradation in dog and guinea pig models of osteoarthritis by the stromelysin inhibitor, BAY 12-9566
12. Molecular changes in human osteoarthritic cartilage after 3 weeks of oral administration of BAY 12-9566, a novel matrix metalloproteinase inhibitor
13. Gender effects in pharmacokinetics and pharmacodynamics
14. Gender-related differences in pharmacokinetics and their clinical significance
15. Gender differences in pharmacokinetics and pharmacodynamics
16. Antipyrine metabolism in man: Influence of age alcohol caffeine, and smoking
17. Drug use in the elderly: A review of problems and special considerations
18. The effects of age and gender on the single dose pharmacokinetics of avitriptan administered to healthy volunteers
19. Single and multiple dose pharmacokinetics of felbamate in the elderly
20. Quinolones in the aged
21. Quantitative HPLC analysis of 4-[4-4-(chlorophenyl)phenyl]-4-oxo-2S-(phenylthiomethyl)butanoic acid (BAY 12-9566), a metalloproteinase inhibitor, and its metabolites in human plasma
22. The pharmacology of aging
23. Pharmacokinetics